Dermata Therapeutics Financials
| DRMA Stock | USD 1.24 0.06 5.08% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.7 K | 1.6 K |
|
|
Investors should never underestimate Dermata Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Dermata Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Dermata Therapeutics.
Net Income |
|
Dermata | Select Account or Indicator |
Understanding current and past Dermata Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Dermata Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Dermata Therapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of Dermata Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Dermata Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Dermata Therapeutics' management manipulating its earnings.
Dermata Therapeutics Stock Summary
Dermata Therapeutics competes with Zura Bio, Phio Pharmaceuticals, Sonnet Biotherapeutics, 180 Life, and Cardio Diagnostics. Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company was incorporated in 2014 and is headquartered in San Diego, California. Dermata Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US2498451085 |
| CUSIP | 249845108 249845306 249845405 |
| Location | California; U.S.A |
| Business Address | 3525 Del Mar |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.dermatarx.com |
| Phone | 858 800 2543 |
| Currency | USD - US Dollar |
Dermata Therapeutics Key Financial Ratios
| Return On Equity | -3.1 | ||||
| EBITDA | (12.51 B) | ||||
| Net Income | (12.29 B) | ||||
| Cash Per Share | 1.05 X | ||||
| Current Ratio | 8.07 X |
Dermata Therapeutics Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 605.5K | 11.6M | 6.9M | 8.0M | 3.5B | 3.7B | |
| Other Current Liab | 133.5K | 1.0M | 425.9K | 757.6K | 1.2M | 730.3K | |
| Net Debt | 3.0M | (10.8M) | (6.2M) | (7.4M) | (3.2M) | (3.3M) | |
| Retained Earnings | (28.1M) | (36.0M) | (45.6M) | (53.4M) | (65.7B) | (62.4B) | |
| Accounts Payable | 104.3K | 515.2K | 496.7K | 866.0K | 808.0K | 573.4K | |
| Cash | 530.4K | 10.8M | 6.2M | 7.4M | 3.2M | 5.5M | |
| Other Current Assets | 75.1K | 825.1K | 690.6K | 532.1K | 612.0K | 483.3K | |
| Total Liab | 3.8M | 1.5M | 922.6K | 1.6M | 2.0B | 2.1B | |
| Net Invested Capital | 367.7K | 10.1M | 6.0M | 6.4M | 1.6M | 1.5M | |
| Total Current Assets | 605.5K | 11.6M | 6.9M | 8.0M | 3.2B | 3.3B | |
| Net Working Capital | (3.2M) | 10.1M | 6.0M | 6.4M | 1.6M | 1.5M |
Dermata Therapeutics Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Net Interest Income | (197.3K) | (45.6K) | 63.6K | 203.4K | 225.8K | 237.1K | |
| Operating Income | (3.2M) | (7.9M) | (9.7M) | (8.0M) | (12.5B) | (11.9B) | |
| Ebit | (3.2M) | (7.9M) | (9.7M) | (7.8M) | (7.0M) | (7.4M) | |
| Research Development | 1.6M | 3.5M | 5.7M | 4.1M | 8.2B | 8.6B | |
| Ebitda | (3.2M) | (7.8M) | (9.7M) | 247.2K | (12.5B) | (11.9B) | |
| Income Before Tax | (3.2M) | (7.9M) | (9.6M) | (7.8M) | (12.3B) | (11.7B) | |
| Net Income | (3.4M) | (7.9M) | (9.6M) | (7.8M) | (12.3B) | (11.7B) | |
| Income Tax Expense | 197.3K | 45.6K | (9.7K) | (8.0K) | (7.2K) | (6.9K) |
Dermata Therapeutics Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (1.5M) | 10.3M | (4.6M) | 1.2M | (4.3B) | (4.1B) | |
| Free Cash Flow | (4.0M) | (5.7M) | (8.8M) | (6.4M) | (11.2B) | (10.6B) | |
| Other Non Cash Items | (36.5K) | 14.1K | 930.3K | 522.1K | 466.4M | 489.7M | |
| Net Income | (3.2M) | (7.9M) | (9.6M) | (7.8M) | (12.3B) | (11.7B) | |
| End Period Cash Flow | 530.4K | 10.8M | 6.2M | 7.4M | 3.2B | 3.3B |
Dermata Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Dermata Therapeutics's current stock value. Our valuation model uses many indicators to compare Dermata Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Dermata Therapeutics competition to find correlations between indicators driving Dermata Therapeutics's intrinsic value. More Info.Dermata Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Dermata Therapeutics' Return On Equity is projected to drop slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Dermata Therapeutics' earnings, one of the primary drivers of an investment's value.Dermata Therapeutics Systematic Risk
Dermata Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Dermata Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fifteen with a total number of output elements of fourty-six. The Beta measures systematic risk based on how returns on Dermata Therapeutics correlated with the market. If Beta is less than 0 Dermata Therapeutics generally moves in the opposite direction as compared to the market. If Dermata Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Dermata Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Dermata Therapeutics is generally in the same direction as the market. If Beta > 1 Dermata Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Dermata Therapeutics Thematic Clasifications
Dermata Therapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
| Pharmaceutical Products | View |
Today, most investors in Dermata Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Dermata Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Dermata Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Dermata Therapeutics March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Dermata Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Dermata Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Dermata Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Dermata Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Dermata Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.72 | |||
| Information Ratio | 0.0742 | |||
| Maximum Drawdown | 31.54 | |||
| Value At Risk | (5.74) | |||
| Potential Upside | 10.0 |
Complementary Tools for Dermata Stock analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |